MedImmune develops medicines for unmet medical needs worldwide. As the global biologics research and development arm of AstraZeneca, MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic including respiratory, inflammation, and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. Since its founding in 1988, MedImmune has remained committed to scientific innovation and medical progress, continually looking beyond standard expectations and pushing the boundaries of what is possible.

FANCL Corp. engages in the manufacture and sale of cosmetics and nutritional supplements. It operates through the following segments: Cosmetics, Nutritional Supplements, and Others. The Cosmetics segment deals with manufacture and sale of cosmetics and provides original equipment manufacturer products. The Nutritional Supplements segment handles manufacture and sale of food supplements. The Others segment includes online sales of undergarments, health equipment, and lifestyle products. It also offers germinated brown rice, kale juice, and esthetic business. The company was founded by Kenji Ikemori in April 1980 and is headquartered in Yokohama, Japan.

Manufactures and sells pharmaceuticals

ProteoNova has created the AcPET system, a platform technology with the ability to address both the increasing cost and the increasing timeline for new product development's discovery and pre-clinical stages. This transformative technology will be able to reduce the out-of-pocket cost for each drug candidate to a few million dollars and the timeline to a few weeks. The cost and time to develop a single protein-based therapeutic, from discovery to FDA submission, is enormous and continues to rise.

MagArray was founded in 2005 by Stanford professors who adapted magnetic sensing technology from the computer disk drive industry for use in medical diagnostics. MagArray technology builds upon the giant magnetoresistive (GMR) nanosensors used as read head elements in computer hard drives to detect biomolecules or biomarkers labeled with magnetic nanoparticles.

Apitope Technology (Bristol) Ltd. is a European biotech company developing therapeutic vaccines for treating autoimmune and allergic diseases, including multiple sclerosis, Type 1 diabetes, Graves' disease, allergies and organ transplant rejection.\nThe team at Apitope is developing potential therapies intended to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system.\nApitope's approach is based on well-established scientific evidence published in leading scientific journals showing that soluble, synthetic peptides can selectively suppress abnormal immune responses and reinstate the normal immune balance and thereby, tolerance.\nThe firm's strategy is to position itself as a significant player in the therapeutic peptide space and make it a partner of choice for pharmaceutical companies keen to develop disease modifiers for autoimmune conditions. It has a highly experienced senior management team, with a proven track record in discovering and developing innovative compounds.\nThe company's lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies.

Ventana Medical Systems, Inc., is a world leader and innovator of tissue-based diagnostic solutions for patients worldwide. The company passionately pursues its mission to improve the lives of all patients afflicted with cancer. Ventana Medical Systems discover, develop, and deliver medical diagnostic systems and biopsy based cancer tests that are shaping the future of healthcare. As the leading supplier of cancer diagnostic systems to the pathology market, Ventana manufactures over 220 cancer tests with related instruments right here in southern Arizona for 80 countries, and most importantly, for 4 million people afflicted with cancer yearly around the world. Ventana products provide healthcare professionals with a total solution for all critical steps involved in the analysis of tissue biopsies. This pioneering company also offers premier workflow solutions to improve laboratory efficiency and preserve patient safety. Ventana is committed to accelerating the discovery and development of new cancer tests that allow pathologists to analyze patient samples at the molecular level to help determine the best course of therapy for each individual patient. Ventana enables this with its global leadership as the number one Pharma Industry Partner of Choice in the development and commercialization of companion diagnostics for cancer patients. Ventana Medical Systems is a member of the Roche Group that is drawing on powerful partnerships with world-class scientific institutions.

Elan Pharmaceuticals LLC develops and manufactures pharmaceutical products. It specializes in treatment of neurological and autoimmune diseases. The firm's drugs are used in the treatment of for Alzheimer's, Parkinson's, and rheumatoid arthritis diseases. The company is headquartered in South San Francisco, CA.

Develops innovative cancer diagnostic products

mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec® Histology kit and CINtec® Cytology kit as adjunct tools for the early detection and diagnosis of cervical cancer.\nThese kits are based on mtm's proprietary E6H4™ antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results.\nmtm laboratories AG also has programs to identify and develop biomarker based diagnostics for other cancer indications. With its extensive and ever increasing network of clinical research institutions, academic research organizations, and medical professionals active in the field of oncology and molecular pathology, mtm has established a rapid, integrated process for the successful identification and clinical validation of molecular markers associated with cancer.

Gendiag Exe SL is a Spanish private company located in Barcelona that engages in research and development in biotechnology.

The Korea Research Institute of Standards and Science (KRISS) is the national measurement standards laboratory for the Republic of Korea. It is a government-funded institute responsible for providing national measurement standards and advancing measurement technologies. KRISS is also an active member of the General Conference on Weights and Measures (CGPM).

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Saraya Co., Ltd. engages in the development, manufacture and sale of household and commercial cleaners, disinfectants, mouthwash hygiene products, chemical supply equipment and food. It also offers consulting for food hygiene and environmental hygiene. The company was founded in 1952 and is headquartered in Osaka, Japan.

Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education. - Identify and assess research projects with commercial potential. - Protect the intellectual property of the Institute and its scientists. - Create business relationships and license the Institute’s inventions and technologies to the industry. - Channel funding from industry to research projects. For further information please contact Tamir Huberman, CIO and Head of Marketing

Wuhan Zhenhao Biotechnology Co., Ltd., established on 2016-02-16, Business scope includes biologics,Tumor Diagnostic Reagents,Stem Cell Technology Development,technical consulting,technology transfer;laboratory reagent(Does not contain dangerous goods)wholesale and retail.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)